OKYO PHARMA LTD (OKYO) Stock Income Statement
USA - NASDAQ:OKYO - GG00BMFG5F62 - Common Stock
1.98 USD
-0.09 (-4.35%)
2.1 USD
+0.12 (+6.06%)
| 2025 (2025-3-31) | 2024 (2024-3-31) | 2023 (2023-3-31) | 2022 (2022-3-31) | 2021 (2021-3-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 7.09M | 15.75M | 13.19M | 4.55M | 2.57M | |||
| Research and Development | 2.25M | 8.24M | 6.34M | 950.00K | 130.00K | |||
| Operating Income | -7.09M | -15.75M | -13.19M | -4.55M | -2.57M | |||
| Interest Income/Expense | -864.80K | -1.05M | -96.70K | 0.00 | 0.00 | |||
| Other Income/Expense | -13.40K | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | 0.00 | -10.00K | |||
| Income Before Taxes | -7.97M | -16.80M | -13.28M | -4.55M | -2.58M | |||
| Income Tax | -3.26M | 22.40K | -12.20K | -580.00K | -20.00K | |||
| Net Income | -4.71M | -16.83M | -13.27M | -3.98M | -2.56M | |||
| EBITDA | -7.09M | -15.75M | -13.18M | N/A | -2.56M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.25 | -1.20 | -1.24 | -36.08 | -33.37 | |||
| Statistics | ||||||||
All data in GBP